Search Results
Found 2 results
510(k) Data Aggregation
(261 days)
The SAFE AT HOME CHOLESTEROL PROFILE Blood Collection and Transport System is intended for over-the-counter distribution, for the self-collection and transportation of dried capillary blood for in vitro diagnostic quantitative determination of Total Cholesterol, HDL-Cholesterol, Triglycerides and Calculated LDL-Cholesterol in dried blood spots. This kit is not intended for use on neonates. LDL cannot be determined where the triglyceride value is greater than 400 mg/dL.
The device is a kit containing the materials necessary to self-collect a capillary blood sample onto a filter paper card for transport to a certified clinical laboratory for lipid profile testing. The kit is comprised of a blood collection card packaged in a foil pouch, alcohol prep pad, disposable lancets, gauze pad, bandage strip, collection instructions, return prepaid envelope, and a patient test authorization form.
The provided text describes a 510(k) premarket notification for the "SAFE AT HOME CHOLESTEROL PROFILE Blood Collection and Transport System." While it mentions performance studies and substantial equivalence, it does not explicitly state specific acceptance criteria or provide a detailed table comparing acceptance criteria with reported device performance.
However, I can infer some general performance aspects and describe the associated study based on the available information:
1. Table of Acceptance Criteria and Reported Device Performance
As specific numerical acceptance criteria are not provided, this table will reflect the general performance claims and the comparison method.
Performance Metric | Acceptance Criteria (Inferred from "Substantially Equivalent") | Reported Device Performance (Summary) |
---|---|---|
Total Cholesterol | Results substantially equivalent to venous (serum) results | Self-collected capillary samples provide results substantially equivalent to venous (serum) results when analyzed using BIOSAFE Laboratories modified analytical methods. |
HDL-Cholesterol | Results substantially equivalent to venous (serum) results | Self-collected capillary samples provide results substantially equivalent to venous (serum) results when analyzed using BIOSAFE Laboratories modified analytical methods. |
Triglycerides | Results substantially equivalent to venous (serum) results | Self-collected capillary samples provide results substantially equivalent to venous (serum) results when analyzed using BIOSAFE Laboratories modified analytical methods. |
LDL-Cholesterol (Calculated) | Results substantially equivalent to venous (serum) results (where triglycerides 400 mg/dL. | |
Precision | Not explicitly stated, but implied to be acceptable for clinical use. | Performance characteristics studied included precision. |
Total Error | Not explicitly stated, but implied to be acceptable for clinical use. | Performance characteristics studied included total error. |
Correlation | Not explicitly stated, but implied to be strong with venous samples. | Performance characteristics studied included correlation. |
Sample Stability | Acceptable stability when exposed to abusive storage and transportation conditions. | Evaluated for sample stability when exposed to abusive storage and transportation conditions. |
2. Sample Size Used for the Test Set and Data Provenance
- Sample Size for Test Set: Not explicitly stated. The document mentions "clinical trials" and "volunteer study subjects," but does not provide the number of subjects or samples.
- Data Provenance:
- Country of Origin: Not explicitly stated, but likely the United States given the FDA submission and the company's address.
- Retrospective or Prospective: The study involved "volunteer study subjects" and the collection of "corresponding venous blood sample and a professionally collected capillary blood sample" alongside the self-collected samples, indicating a prospective study design.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Qualifications of Those Experts
This device is for in vitro diagnostic determination of lipid profiles, not interpretation by human experts. The ground truth would be established by laboratory analysis using predicate devices and validated methods, not expert consensus. Therefore, this section is not applicable in the traditional sense of human expert review.
4. Adjudication Method for the Test Set
Not applicable. The "ground truth" for lipid levels is determined by established laboratory analytical methods, not by adjudication among human readers.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and the Effect Size
No, an MRMC comparative effectiveness study was not done. This type of study is relevant for imaging or diagnostic devices where human interpretation plays a significant role. For this in vitro diagnostic device, the comparison is between blood collection methods (self-collected capillary vs. venous/professionally collected capillary) and their analytical results.
6. If a Standalone (i.e. algorithm only without human-in-the-loop performance) Was Done
This question is not directly applicable in the context of this device. The "device" is a blood collection and transport system. The analysis of the blood samples is performed by standard laboratory instruments and reagents (Synermed Cholesterol Reagent Kit, Sigma Diagnostics Infinity Triglyceride Reagents, Sigma Diagnostics EZ-HDL Cholesterol Reagents), which can be considered "standalone" in their analytical capacity once the sample is prepared. The study evaluates the sample quality and the method modifications used by BIOSAFE Laboratories to analyze these specific dried capillary blood spots.
7. The Type of Ground Truth Used
The ground truth used was comparative laboratory results from venous (serum) blood samples and professionally collected capillary blood samples, analyzed using predicate or established laboratory methods. This acts as the "gold standard" against which the self-collected capillary samples were compared.
8. The Sample Size for the Training Set
The document does not explicitly mention a separate "training set" for the device itself. The primary study described is a performance study comparing different sample types. If there was an internal development or optimization phase for their "modified analytical methods," the sample size used for that is not specified.
9. How the Ground Truth for the Training Set Was Established
As no explicit training set for the device is mentioned, this is not applicable. The "ground truth" for the overall validation was established by standard laboratory analysis of venous and professionally collected capillary blood, as described in point 7.
Ask a specific question about this device
(93 days)
The BIOSAFE CHOLESTEROL PROFILE Blood Collection and Transport System is intended for prescription distribution, and is a clinic-use device for collection and transportation of dried capillary blood for in vitro diagnostic quantitative determination of Total Cholesterol, HDL-Cholesterol, Triglycerides and Calculated LDL-Cholesterol in dried blood spots. This kit is not intended for use on neonates. LDL cannot be determined where the triglyceride value is greater than 400 mg/dL.
The device is a kit containing the materials necessary to collect a capillary blood sample onto a filter paper card for transport to a certified clinical laboratory for lipid profile testing. The kit is comprised of a blood collection card packaged in a foil pouch, alcohol prep pad, disposable lancets, gauze pad, bandage strip, collection instructions, return prepaid envelope, and a patient test authorization form.
Here's an analysis of the provided text to extract the acceptance criteria and details about the study proving device performance:
1. Table of Acceptance Criteria and Reported Device Performance
The provided document (K011970) is a 510(k) summary for a blood collection and transport system, primarily focusing on demonstrating substantial equivalence to predicate devices rather than establishing specific performance acceptance criteria with numerical targets.
The document states: "Results of clinical trials show that professionally collected capillary samples onto the BIOSAFE Blood Collection Card provide results that are substantially equivalent to venous (serum) results for Total Cholesterol, HDL Cholesterol and Triglycerides when analyzed using BIOSAFE Laboratories modified analytical methods."
It further states: "Determination of professionally collected capillary blood Total 7) Performance Studies Cholesterol, HDL Cholesterol and Triglycerides using the BIOSAFE CHOLESTEROL PROFILE Blood Collection and Transport System is substantially equivalent to venous (serum) samples for lipid profile BIOSAFE Laboratories modified analytical methods testing."
Given this, the acceptance criteria are qualitative, centered around robust statistical equivalence to established venous blood testing methods, rather than specific numerical thresholds for accuracy, sensitivity, or specificity. The device performance is reported as meeting this "substantial equivalence."
Acceptance Criteria (Stated Qualitatively) | Reported Device Performance |
---|---|
Substantial equivalence to venous (serum) results for total cholesterol | Provided results substantially equivalent to venous (serum) results for Total Cholesterol |
Substantial equivalence to venous (serum) results for HDL cholesterol | Provided results substantially equivalent to venous (serum) results for HDL Cholesterol |
Substantial equivalence to venous (serum) results for triglycerides | Provided results substantially equivalent to venous (serum) results for Triglycerides |
Capable of determining Calculated LDL-Cholesterol | Yes, when triglyceride values are not greater than 400 mg/dL |
Stability of samples under abusive storage/transportation conditions | Evaluated; performance characteristics studied included precision, linearity and correlation, and sample stability |
2. Sample Size Used for the Test Set and Data Provenance
- Sample Size: The document does not explicitly state a specific number for the sample size. It mentions "volunteer study subjects" and "professionally collected blood samples from volunteer study subjects at three different geographical sites."
- Data Provenance: The study was conducted using prospective data collection. The subjects were volunteers, and samples were collected specifically for this study. The data was collected from "three different geographical sites." The country of origin is not explicitly stated, but given the FDA 510(k) submission, it's highly likely to be the United States.
3. Number of Experts Used to Establish the Ground Truth for the Test Set and Their Qualifications
The document does not describe the use of "experts" to establish ground truth in the traditional sense of image or clinical interpretation.
- The ground truth for the study was established by laboratory analysis of venous blood samples using FDA-Cleared laboratory reagent and analysis systems. The "experts" in this context would be the certified clinical laboratory professionals performing the analyses and the established analytical methods themselves. The document states: "A corresponding venous blood sample was collected by the health care professional in order to compare serum lipid results to those obtained from capillary blood samples collected onto the BIOSAFE Blood Collection Card."
4. Adjudication Method for the Test Set
Not applicable. This is not a study involving human readers or interpretation where an adjudication method like 2+1 or 3+1 would be relevant. The ground truth was based on laboratory analysis, which inherently includes internal quality controls and standardized procedures.
5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done
No, an MRMC comparative effectiveness study was not done. This study is focused on the analytical performance of the collection and transport system against standard laboratory methods, not on human reader performance with or without AI assistance.
6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done
Yes, in a way. The "device" in question is a blood collection and transport system. The performance study evaluates the standalone analytical performance of the collected capillary blood samples (after transport and preparation) when run on standard laboratory analytical systems (Synermed Cholesterol Reagent Kit, Sigma Diagnostics Infinity Triglyceride Reagents, Sigma Diagnostics EZ-HDL Cholesterol Reagents). The "algorithm" here is the combined process of collection, transport, and subsequent laboratory analysis, without direct human intervention in the final analytical measurement itself. The comparison is between the results from the dried capillary blood spots via this process and the results from standard venous serum samples.
7. The Type of Ground Truth Used
The type of ground truth used was laboratory analysis results from venous (serum) blood samples. These are considered the gold standard for lipid profile determination.
8. The Sample Size for the Training Set
Not applicable. This type of device and study does not involve a "training set" in the context of machine learning or AI development. The device's performance is based on its physical/chemical properties and the established analytical methods, not on a learned model.
9. How the Ground Truth for the Training Set Was Established
Not applicable, as there is no training set for this device.
Ask a specific question about this device
Page 1 of 1